Where is the right place for immunotherapy for advanced kidney cancer?

02/2018

MUDr. Hana Študentová, Ph.D.

Onkologická klinika LF UK a FN Olomouc

SUMMARY

Targeted therapy of renal cell carcinoma has evolved enormously during past ten years. Inhibitors of angiogenesis have dominated exclusively in the treatment algorithm until recently, when immunotherapy has become a potential rival. Immunotherapy has been going through a revival due to a different and attractive mechanism of fight against cancer. New molecules have emerged to show efficacy with a regard of response rate, improving survival outcome, however, the key question remains unanswered - what is the optimal sequence of therapy including immunotherapy in the treatment of renal cell carcinoma?

KEY WORDS

immunotherapy, renal carcinoma, checkpoint inhibitors, nivolumab, pembrolizumab